Effect of Subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
The number to watch here is not just whether glucose drops, but whether it drops too far
RACGP Expert Committee Quality Care member, Associate Professor Magda Simonis, is sceptical of the results
It upregulates the expression of CYP8B1 and increases tauroursodeoxycholic acid (TUDCA) levels, which in turn inhibits the expression and activity of XOD, ultimately leading to a reduction in the production of UA (129)
It suits people who value convenience, medication delivery, and clinical follow up via app messaging
Movement: Walk 15 minutes daily, no intense exercise